ARTICLE | Clinical News

LJP 394 data

May 1, 1995 7:00 AM UTC

The San Diego company announced that four patients enrolled in the open-label part of a Phase II trial showed reduced levels of antibodies to double-stranded DNA. The antibodies are the hallmark of lupus-induced kidney damage. A single 100 mg dose resulted in the decline. ...